Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374278 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
A Phase 1 study of Alzheimer Disease and Dementia, sponsored by David Wilson.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT05374278 is a Phase 1 study of Alzheimer Disease and Dementia that is actively recruiting participants, run by David Wilson. The registered enrollment target is 102 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05374278, a Phase 1 study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by David Wilson.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
Conditions Studied
Interventions
- DRUG [18F]RP-115 PET/MRI or PET/CT and MRI
Study Locations (1)
California
- China Basin, UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05374278
The ClinicalTrials.gov registry entry for NCT05374278 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is David Wilson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]RP-115 PET/MRI or PET/CT and MRI is the first listed.
NCT05374278 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05374278 about?
NCT05374278 is a clinical study titled "First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia". This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD...
What is the current status of trial NCT05374278?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2021-11-02. Estimated completion is 2027-05-31.
What conditions does trial NCT05374278 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Frontotemporal Dementia.
What interventions are being tested in trial NCT05374278?
The interventions under investigation include: [18F]RP-115 PET/MRI or PET/CT and MRI (DRUG).
Who is sponsoring clinical trial NCT05374278?
This trial is sponsored by David Wilson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05374278 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.